Astex Pharma (ASTX) sNDA for Dacogen Declined by FDA; Did Not Show Statistical Superiority
Tweet
Share
E-mailGet Alerts ASTX Hot Sheet
Join SI Premium – FREE
Astex Pharmaceuticals, Inc. (Nasdaq: ASTX) reports that the U.S. Food and Drug Administration has issued a Complete Response Letter to partner Eisai for their supplemental New Drug Application (sNDA) for Dacogen® (decitabine) for Injection for patients with acute myeloid leukemia (AML) in adults 65 years of age or older who are not considered candidates for induction therapy.
The FDA declined to approve the application because the pre-specified analysis of the primary endpoint in the study (DACO-016) did not demonstrate statistically significant superiority of Dacogen over the control arm (p=0.11).
The FDA declined to approve the application because the pre-specified analysis of the primary endpoint in the study (DACO-016) did not demonstrate statistically significant superiority of Dacogen over the control arm (p=0.11).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Hinge Health signs $86M office lease in San Francisco
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
